IGF2BP2 Drives PTCL Growth and Immune Evasion, Offers Therapeutic Target

Peripheral T-cell lymphomas (PTCLs) are a group of aggressive lymphoid neoplasms marked by significant heterogeneity, which contributes to their often poor prognosis and resistance to standard therapies [1, 2]. The complex interplay between tumor cells and their microenvironment, particularly mechanisms of immune suppression, is a known factor in cancer progression and therapeutic failure [3, 4]. In recent years, epigenetic modifications affecting RNA have emerged as critical regulators of gene expression in both health and disease, including cancer [5, 6, 7]. Aberrant RNA modifications can drive tumor development and help create an immunosuppressive tumor microenvironment [4]. A recent study provides new molecular details on a protein that appears to orchestrate both tumor growth and immune evasion in PTCL.